Affinity DataIC50: 6.70E+3nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 8.40E+3nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 9.10E+3nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 9.70E+3nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.17E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.19E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.35E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.51E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.54E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.82E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.83E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.88E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 1.98E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 4.20E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 4.46E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.09E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 5.91E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 6.27E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 6.27E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 6.44E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair
Affinity DataIC50: 6.96E+4nMAssay Description:Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hr...More data for this Ligand-Target Pair